QLGN vs. CMND, LSDI, BPTH, GLMD, SLRX, PRFX, NTBL, CNSP, DRMA, and INM
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Clearmind Medicine (CMND), Lucy Scientific Discovery (LSDI), Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), Salarius Pharmaceuticals (SLRX), PainReform (PRFX), Notable Labs (NTBL), CNS Pharmaceuticals (CNSP), Dermata Therapeutics (DRMA), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical preparations" industry.
Clearmind Medicine (NASDAQ:CMND) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
Qualigen Therapeutics' return on equity of -265.38% beat Clearmind Medicine's return on equity.
Qualigen Therapeutics received 7 more outperform votes than Clearmind Medicine when rated by MarketBeat users.
Clearmind Medicine has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500.
96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 5.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Clearmind Medicine has higher earnings, but lower revenue than Qualigen Therapeutics.
In the previous week, Clearmind Medicine and Clearmind Medicine both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Clearmind Medicine'saverage media sentiment score.
Summary
Clearmind Medicine beats Qualigen Therapeutics on 5 of the 8 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
